Your search returned 2 results.

Sort
Unhighlight Highlight
Select all Clear all
Select titles to:
Results
1.
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 29246950
Year: 2018
Citation:
  • Diabetes Care. 41(2):258-266, 2018 02.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
DOI:
Add to cart
2.
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 28344112
Year: 2017
Citation:
  • The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
DOI:
Add to cart
Pages

Powered by Koha